UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

The combination of cyclophosphamide, velcade and dexamethasone (CVD) induces high response rates with comparable toxicity to velcade alone (V) and velcade plus dexamethasone (VD)

Haematologica (Roma), 2007-08, Vol.92 (8), p.1149-1150

2007

Volltextzugriff (PDF)

Ocular and cerebral aspergillosis in a non-neutropenic patient following alemtuzumab and methyl prednisolone treatment for chronic lymphocytic leukaemia

Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 2010-04, Vol.16 (2), p.150-151

2010

Volltextzugriff (PDF)

Response to first vaccination against SARS-CoV-2 in patients with multiple myeloma

The Lancet. Haematology, 2021-06, Vol.8 (6), p.e389-e392

2021

Volltextzugriff (PDF)

Survival and outcome of blastoid variant myeloma following treatment with the novel thalidomide containing regime DT-PACE

European journal of haematology, 2008-12, Vol.81 (6), p.432-436

2008

Volltextzugriff (PDF)

P-144: Response to SARS-CoV-2 vaccination in patients with Multiple Myeloma using a 12-week spaced dosing strategy

Clinical lymphoma, myeloma and leukemia, 2021-10, Vol.21, p.S114-S114

2021

Volltextzugriff (PDF)

Carcinomatous infiltration of cerebrospinal fluid with reactive lymphocytosis and granulocytosis

American journal of hematology, 2010-10, Vol.85 (10), p.791-791

2010

Volltextzugriff (PDF)

Bendamustine, Thalidomide and Dexamethasone is an effective salvage regimen for advanced stage multiple myeloma

British journal of haematology, 2012-02, Vol.156 (4), p.552-555

2012

Volltextzugriff (PDF)

Bone marrow transplants for paroxysmal nocturnal haemoglobinuria

British journal of haematology, 1999-02, Vol.104 (2), p.392-396

1999

Volltextzugriff (PDF)

The Natural History of Myeloma Patients Who Relapse Early After High Dose Therapy

Blood, 2012-11, Vol.120 (21), p.3125-3125

2012

Volltextzugriff (PDF)

The Introduction of Novel Agents Improves Outcomes of Young Patients with Myeloma (MM) Treated with Autologous Stem Cell Transplant (ASCT)

Blood, 2010-11, Vol.116 (21), p.1348-1348

2010

Volltextzugriff (PDF)

Chronic graft versus host disease is associated with long-term risk for pneumococcal infections in recipients of bone marrow transplants

Blood, 2000-06, Vol.95 (12), p.3683-3686

2000

Volltextzugriff (PDF)

Long‐term outcomes of previously untreated myeloma patients: responses to induction chemotherapy and high‐dose melphalan incorporated within a risk stratification model can help to direct the use of novel treatments

British journal of haematology, 2005-06, Vol.129 (5), p.607-614

2005

Volltextzugriff (PDF)

Autologous Transplantation Is the Optimum Approach to the Management of Myeloma Patients with Extramedullary Disease at Presentation

Blood, 2008-11, Vol.112 (11), p.3313-3313

2008

Volltextzugriff (PDF)

Maintenance Chemotherapy (MC) after Autotransplantation in First-Remission Acute Lymphoblastic Leukemia (ALL): Single-Center Experience of 100 Patients

Blood, 2007-11, Vol.110 (11), p.2874-2874

2007

Volltextzugriff (PDF)

Outcomes of Patients with Hematological Malignancies Admitted to Critical Care

Blood, 2006-11, Vol.108 (11), p.5289-5289

2006

Volltextzugriff (PDF)

Duration of Initial Admission and Subsequent Readmission in the First 100 Days Following Reduced Intensity Conditioning Allogeneic Stem Cell Transplantation

Blood, 2007-11, Vol.110 (11), p.1999-1999

2007

Volltextzugriff (PDF)

The Combination of Cyclophosphamide, Velcade and Dexamethasone (CVD) Induces High Response Rates with Minimal Toxicity Compared to Velcade Alone (V) and Velcade Plus Dexamethasone (VD)

Blood, 2006-11, Vol.108 (11), p.3537-3537

2006

Volltextzugriff (PDF)

Lymphocyte Count on Day 56 Predicts for Reduced Risk of Infection Related Mortality Following Non-Myeloablative Allogeneic Haematopoietic Stem Cell Transplantation

Blood, 2006-11, Vol.108 (11), p.5324-5324

2006

Volltextzugriff (PDF)

Lenolidamide (Revlimid), in Combination with Cyclophosphamide and Dexamethasone (CRD) Is an Effective Regimen for Heavily Pre-Treated Myeloma Patients

Blood, 2006-11, Vol.108 (11), p.3555-3555

2006

Volltextzugriff (PDF)

Incidence of Second Malignant Neoplasms (SMN) after Haematopoetic Stem Cell Transplant

Blood, 2006-11, Vol.108 (11), p.551-551

2006

Volltextzugriff (PDF)

A Comparative Analysis of Outcomes in Primary Myelodysplastic Syndrome (MDS) and Therapy-Related MDS Reveals Two Subgroups with Differing Risk Profiles: Implications for the Application of a Prognostic Classification

Blood, 2005-11, Vol.106 (11), p.2532-2532

2005

Volltextzugriff (PDF)

Clinical profile and outcome of urotheliotropic viral haemorrhagic cystitis following haematopoietic stem cell transplantation: a 7-year tertiary centre analysis

Hematology (Luxembourg), 2011-07, Vol.16 (4), p.213-220

2011

Volltextzugriff (PDF)

Pregnancy Outcome Following Haematopoietic Stem Cell Transplantation

Blood, 2006-11, Vol.108 (11), p.3367-3367

2006

Volltextzugriff (PDF)

Responses to Induction Chemotherapy and High Dose Melphalan Can Be Incorporated within a Risk Stratification Model and Help to Identify Myeloma Patients Who May Benefit from Novel Therapies

Blood, 2004-11, Vol.104 (11), p.2394-2394

2004

Volltextzugriff (PDF)

Bone marrow transplants for parozysmal nocturnal haemoglobinuria

British journal of haematology, 1999-02, Vol.104 (2), p.392

1999

Volltextzugriff (PDF)

1 – 25 von 32

Suche als RSS-Feed

Aktive Filter

Zeitschrift / SerieLeukemia & Lymphoma

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(32)
Mit Volltextzugriff
(30)

Publikationsform

Artikel
(32)

Sprache

Englisch
(32)

Erscheinungsjahr

n.n

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

The combination of cyclophosphamide, velcade and dexamethasone (CVD) induces high response rates with comparable toxicity to velcade alone (V) and velcade plus dexamethasone (VD)

Ocular and cerebral aspergillosis in a non-neutropenic patient following alemtuzumab and methyl prednisolone treatment for chronic lymphocytic leukaemia

Response to first vaccination against SARS-CoV-2 in patients with multiple myeloma

Survival and outcome of blastoid variant myeloma following treatment with the novel thalidomide containing regime DT-PACE

P-144: Response to SARS-CoV-2 vaccination in patients with Multiple Myeloma using a 12-week spaced dosing strategy

Carcinomatous infiltration of cerebrospinal fluid with reactive lymphocytosis and granulocytosis

Bendamustine, Thalidomide and Dexamethasone is an effective salvage regimen for advanced stage multiple myeloma

Bone marrow transplants for paroxysmal nocturnal haemoglobinuria

The Natural History of Myeloma Patients Who Relapse Early After High Dose Therapy

The Introduction of Novel Agents Improves Outcomes of Young Patients with Myeloma (MM) Treated with Autologous Stem Cell Transplant (ASCT)

Chronic graft versus host disease is associated with long-term risk for pneumococcal infections in recipients of bone marrow transplants

Long‐term outcomes of previously untreated myeloma patients: responses to induction chemotherapy and high‐dose melphalan incorporated within a risk stratification model can help to direct the use of novel treatments

Autologous Transplantation Is the Optimum Approach to the Management of Myeloma Patients with Extramedullary Disease at Presentation

Maintenance Chemotherapy (MC) after Autotransplantation in First-Remission Acute Lymphoblastic Leukemia (ALL): Single-Center Experience of 100 Patients

Outcomes of Patients with Hematological Malignancies Admitted to Critical Care

Duration of Initial Admission and Subsequent Readmission in the First 100 Days Following Reduced Intensity Conditioning Allogeneic Stem Cell Transplantation

The Combination of Cyclophosphamide, Velcade and Dexamethasone (CVD) Induces High Response Rates with Minimal Toxicity Compared to Velcade Alone (V) and Velcade Plus Dexamethasone (VD)

Lymphocyte Count on Day 56 Predicts for Reduced Risk of Infection Related Mortality Following Non-Myeloablative Allogeneic Haematopoietic Stem Cell Transplantation

Lenolidamide (Revlimid), in Combination with Cyclophosphamide and Dexamethasone (CRD) Is an Effective Regimen for Heavily Pre-Treated Myeloma Patients

Incidence of Second Malignant Neoplasms (SMN) after Haematopoetic Stem Cell Transplant

A Comparative Analysis of Outcomes in Primary Myelodysplastic Syndrome (MDS) and Therapy-Related MDS Reveals Two Subgroups with Differing Risk Profiles: Implications for the Application of a Prognostic Classification

Clinical profile and outcome of urotheliotropic viral haemorrhagic cystitis following haematopoietic stem cell transplantation: a 7-year tertiary centre analysis

Pregnancy Outcome Following Haematopoietic Stem Cell Transplantation

Responses to Induction Chemotherapy and High Dose Melphalan Can Be Incorporated within a Risk Stratification Model and Help to Identify Myeloma Patients Who May Benefit from Novel Therapies

Bone marrow transplants for parozysmal nocturnal haemoglobinuria

Aktive Filter

Suchergebnisse filtern